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Abstract: Lung cancer (LC) remains the most common cause of cancer death in several countries 
across the world. Fatigue is the most frequently reported symptom in LC patients throughout 
the entire course of disease, and all international guidelines recommend early screening for 
cancer-related fatigue (CRF) and symptoms that can affect patients’ quality of life. In patients 
with LC, fatigue belongs to the symptom cluster of pain, depression, and insomnia, which are 
commonly observed simultaneously, but are typically treated as separate although they may have 
common biological mechanisms. The treatment of CRF remains one of the difficult areas in the 
oncology field: scarce evidence supports pharmacological therapies, while some interesting data 
arising indicates alternative remedies and physical exercise seem to be one of the most effective 
approaches for CRF at any stage of LC.
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Introduction
Lung cancer (LC) remains the most common cause of cancer-related death, accounting 
for approximately 20% of the total cancer death worldwide. Despite important prog-
ress occurring in diagnostic and therapeutic areas, only 10.9% of people with LC live 
5 years or more.1 Several trials have shown that the physical symptoms have a great 
importance in cancer patients, especially in LC.2,3 A number of cluster symptoms such 
as anxiety, fatigue, and dyspnea have been associated with poor patient performance, 
and these often remain a major issue throughout the course of cancer treatment and 
thereafter.4 Cancer-related fatigue (CRF) is present during the entire course of the 
disease, resulting in the impairment of both day-to-day living and overall quality of 
life (QoL).5,6 CRF is defined as a distressing, persistent, subjective sense of physical, 
emotional, and/or cognitive tiredness or exhaustion related to cancer and/or cancer 
treatment, and it is not strictly linked to recent activity and nor is it relieved by rest.7 
Furthermore, patients with LC indicate relief from tiredness as the most common 
unmet need, even years after diagnosis.8 Fatigue is the most represented acute symp-
tom before and after cancer treatment, affecting a large number of patients, ranging 
between 57% and 100% of the cases,9 rarely described as an isolated symptom and 
often associated with depression and sleep disorders.10 Different causes can justify 
the onset of fatigue in a patient with cancer, together with cancer itself, such as 
comorbidities, nutritional status, medications, the reduction of physical activity, and 
functional status. Different international guidelines have been published regarding the 
management of CRF, with no specific medication approved to date.7,11,12 Aware of the 
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lack of data in the  literature, this paper aims to summarize 
methods of  identification and possible treatments of CRF 
in LC, with the purpose of  suggesting a strategy for a more 
comprehensive and effective approach.
Material and methods
Articles from 1997 to 2016 were selected using PubMed, 
which is a very large research database, using as keywords 
only “fatigue” and “lung cancer”. Subsequently, the articles 
were divided according to the different paragraphs of this 
review: assessment, fatigue and symptoms cluster, fatigue in 
several stages of disease, fatigue in active therapies, and, in 
conclusion, the possible therapeutic approaches. The data 
collected include more robust evidence and alternate strategy 
for managing fatigue in patients with LC. The management 
of this symptom must involve team effort, and for this reason 
our review paper is addressed to physicians and nurses.
Assessment of CRF
Fatigue has to be screened and scored according to the clini-
cal practice guidelines.11–13 Any patient must, therefore, be 
evaluated for severity, duration, and alleviation of factors 
of CRF from the first visit and during the course of the 
disease. In addition, the type of fatigue must be identified, 
considering that CRF can be categorized as either primary 
or secondary.13 Primary fatigue is linked to the tumor itself 
or alterations caused by cytokines produced during cancer 
treatment14 as a disturbance of hypothalamic regulatory 
circuits,15 changes in the central serotoninergic system, and 
alteration of circadian melatonin secretion.16 Factors playing 
a key role in fatigue development include polymorphisms 
in genes coding regulatory proteins of oxidative phospho-
rylation, signal transduction in B-cells, the expression of 
proinflammatory cytokines, and catecholamine metabolism.17 
Secondary fatigue is caused by one or more disease-related 
symptom(s) such as sleep disturbance, infection, malnutri-
tion, or anemia. Moreover, CRF can be closely linked to 
comorbidities, the presence of emotional distress or pain, the 
physical activity status, alcohol/substance abuse, and use of 
medications (Table 1). In the CRF evaluation, it is extremely 
relevant to consider the timing of the disease, in terms of 
recent diagnosis, disease progression/recurrence, follow-up 
period, or end of life. As previously mentioned, the correct 
identification and score of CFR is a fundamental step in treat-
ment decision. Screening can be done through quantitative 
and semiquantitative scales, even if these assessments are 
more appropriate for secondary CRF and a validated scale, 
specific for CRF in LC, is currently not available. Among the 
most used scales are the following: Brief Fatigue Inventory 
(BFI), Functional Assessment of Cancer Therapy-Fatigue, 
Cancer Fatigue Scale, Multidimensional Fatigue Inventory, 
and the European Organisation for Research and Treatment 
of Cancer Quality of Life Questionnaire-Core 30.18 BFI is 
the most common questionnaire included in LC clinical 
trials and is also useful in detecting the severity of fatigue 
occurring during the previous 24 hours together with the 
CRF impact on individual’s life. Preliminary data reported 
in the literature suggest a possibility of integration of clinical 
and molecular assessment in detecting fatigue in LC. In fact, 
interesting data have been reported about the role of potential 
predictive biomarkers for primary CRF in non-small-cell lung 
cancer (NSCLC). A recent Chinese study showed, in 100 
LC patients, a correlation of CRF and different factors such 
as tumor necrosis factor (TNF)-α and interleukin (IL)-1 at 
the plasma level and 17-hydroxycorticosteroid in the urine, 
collected before and after chemotherapy. This correlation is 
statistically significant for TNF-α and IL-1, and fatigue was 
reported by 88% of patients.19 The use of validated scales 
(such as BFI) should always be applied to detect and grade 
fatigue in LC, not only in the research area but also in clini-
cal practice.
Fatigue and cluster symptoms
The majority of patients with LC experience debilitating 
physical and psychological symptoms. Pain, depression, 
and fatigue are among the most frequent symptoms reported 
by LC patients, and their frequency and intensity increase 
with the approach of death (P=0.001).20,21 Symptoms are 
commonly observed to co-occur in a related cluster and can 
be induced by common biological mechanisms, but are typi-
cally treated as separate entities. It has been established that 
depression is present in about one-third of patients with LC. 
In a group of 987 patients, depression before treatment was 
present in 322 (33%) cases and persists in more than 50% 
Table 1 Causes of CRF
Causes of CRF
Primary CRF Alterations caused by cytokines, disturbance of 
hypothalamic regulatory circuits, changes in the 
central nervous system serotoninergic system, 
disturbance of circadian melatonin secretion, gene 
polymorphisms for regulatory proteins of oxidative 
phosphorylation
Secondary CRF Sleep disturbance, infection, anemia, malnutrition, 
emotional distress, pain, reduced physical activity, 
alcohol/substance abuse, use of medications, 
comorbidities as COPD
Abbreviations: CRF, cancer-related fatigue; COPD, chronic obstructive pulmonary 
disease.
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of them through the course of the disease. In this trial, it 
was shown that small-cell lung cancer (SCLC) patients had 
a threefold greater prevalence of depression than those with 
NSCLC (25% versus 9%; P,0.0001).22 It is estimated that 
74%–90% of patients with LC experience pain, and several 
studies report similar rates of incidence for fatigue and 
insomnia. A recent study reports a simultaneous incidence 
of fatigue, pain, and insomnia, in the range of 40%–50% of 
cases.52 In another trial of 111 patients with solid cancer (the 
largest group with LC, 20%), it was observed that the preva-
lence of pain, fatigue, insomnia, and somnolence were 100%, 
50%, 80%, and 82%, respectively. All the aforementioned 
rates suggest a strong correlation between fatigue, pain, and 
sleep disorders.23 Genetic polymorphisms in LC, such as 
mutant alleles in endothelial nitric oxide synthase, seem to 
be helpful in the identification of high-risk patients for these 
symptom clusters and also have the potential for development 
of personalized therapies.24 A qualitative study of LC patient 
symptoms indicates that the cluster of respiratory symptoms 
(such as cough and breathlessness) plays a central role in 
fatigue onset.6 Taking into consideration this type of interac-
tion between symptom clusters, a single intervention should 
be successful to treat them simultaneously, and this approach 
could improve the perception of each single symptom.25
Fatigue in early-stage LC and in survivors
Improvements in curative therapies have led to increased 
number of cancer survivors: for this reason, recent guide-
lines have been published to detect, grade, and treat CRF in 
adult cancer survivors (including LC patients) after comple-
tion of primary treatment.12,26 The symptom in this specific 
subgroup of LC patients could be due to comorbidities and 
treatments prescribed to cope with surgical consequences 
and/or  adjuvant chemo/radiotherapy. Nearly 60% of NSCLC 
survivors are affected by comorbidities, 50% with forced 
expiratory volume in 1 second (FEV
1
) ,70%, 22% reported 
distressed mood, and 21% of them had severe functional 
restrictions.27 These deficits can promote the onset and/or 
worsening of fatigue, as reported in several publications.28,29 
Among LC survivors, the prevalence of fatigue is close to 
70% at 4 months after thoracotomy.30 In 350 patients surgi-
cally treated for early-stage NSCLC, the prevalence of fatigue 
was 57%, with 47% of patients indicating mild fatigue and 
17% experiencing moderate-to-severe fatigue.29 Recent 
data among 254 completely resected patients with stage IA 
(57.1% of the  population) or IB NSCLC (lobectomy was 
performed in 77.2% of cases) show an overall incidence of 
postoperative fatigue equal to 59.8% (37.4% mild and 22.4% 
moderate-to-severe fatigue). The association between fatigue 
and functional status and FEV
1
/FVC (the proportion of a 
person’s vital capacity that they are able to expire in the first 
second of forced expiration) was considered before and after 
surgery, with a mean time from surgery to evaluation equal 
to 2.9±1.5 years. Before surgery, 59.8% of patients showed 
a slight decline in lung function (FEV
1
/FVC 61%–70%), 
and 43.3% had chronic bronchitis, chronic obstructive 
pulmonary disease (COPD), asthma, tuberculosis, or other 
lung diseases. The prevalence of anxiety and depression 
after surgery was 18.5% and 10.2%, respectively, indicat-
ing that LC itself, together with the specific interventions, 
may have huge negative effects on the psychological well-
being. It has been shown that moderate-to-severe fatigue 
was negatively associated with preoperative FEV
1
/FVC and 
physical activity and positively related to functional status, 
concurrent lung diseases, breathing difficulty, depression, 
and anxiety.31 Several studies demonstrated that functional 
status, concurrent lung diseases, depression, and anxiety are 
independent risk factors for fatigue, whereas physical activ-
ity was a protective factor.24,35 A recent meta-analysis found 
a strong negative correlation between CRF and continued 
smoking after surgical treatment.32 It is, therefore, strongly 
recommended to increase smoking cessation programs in this 
 setting of patients: continuing smoking can worsen respira-
tory disorders already present, comorbidity, and also fatigue. 
Data about the persistence of fatigue in survivors are still 
controversial; one trial reported a resolution of symptoms33 
at 3–6 months after surgery,33 while others have observed 
persistence for years after completion of treatment.34,35 In 
addition to the surgical approach, adjuvant treatment can also 
cause long-term toxicities: sensory neuropathy and hearing 
loss occured in approximately 45% and 21% of patients who 
underwent adjuvant platinum-based chemotherapy, together 
with worsening of CFR and decline of global QoL.36 In fact, 
in a phase III study of adjuvant chemotherapy (JBR.10 trial), 
global QoL of patients decreases both in the observation 
and chemotherapy arms, mainly because of fatigue and post 
surgical pain. Patients in the observation arm had a faster 
physical recovery: at 3 months. The QoL in patients who 
received chemotherapy was comparable to the observation 
arm at a median time of 9 months after surgery.37 In this trial, 
psychological distress was reported in almost 40% of NSCLC 
survivors,38 which is significantly higher than in other cancer 
survivors. Literature data provide evidence that the surgical 
and adjuvant therapies may, in some cases, lead to a reduced 
QoL, in particular with the appearance (or worsening) of the 
symptom cluster associated with the CFR.
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Fatigue and active therapies in LC
Patients receiving chemotherapy or radiotherapy report fatigue 
during treatment in 90% and from 65% to 100% of cases, 
respectively.39,40 Currently, physicians have few tools to cope 
with this symptom. A wide spectrum of health care needs is 
widely described by patients with LC and can be grouped 
into nine distinct domains: physical, daily living, psychologi-
cal/emotional, spiritual/existential, informational, practical, 
communication, social and family related, and  cognitive. It 
is well recognized that active treatment for LC causes a high 
physical impact on patients.41 In a recent prospective multi-
center QoL study in patients treated for NSCLC, fatigue 
was the most frequently reported physical disorder. Before 
completing the questionnaires, almost 60% of patients had 
undergone chemotherapy and about 10% received radio- or 
chemotherapy. In the multivariate analysis including age, sex, 
tumor stage, and fatigue, only the latter was found to be an 
independent prognostic factor affecting survival.42 In cancer 
patients (including LC patients) during chemotherapy treat-
ment, diurnal variations of severe fatigue were identified.43,44 
Morning and evening fatigue appear as distinct symptoms, 
both having a negative impact on prognosis. Interestingly, 
marital status, annual household income, body mass index, 
regular exercise, and a state of anxiety are associated only with 
morning fatigue, while among predictors of evening fatigue, 
child-care responsibilities, ethnicity (greater correlation with 
white patients), cancer diagnosis (patients with LC), and prior 
cancer treatment are reported as factors. Other factors like 
age, sex, functional status, comorbidity profile, depressive 
symptoms, sleep disturbance, and annual income of ,$30,000 
may influence both morning and evening fatigue. In particular, 
younger age is associated with the highest levels with morning 
and evening fatigue.45,46 Data on the relationship between age 
and fatigue are also described in a trial which explored radia-
tion therapy as a therapeutic approach.47 Different potential 
explanations for these results could be the administration of 
lower doses of chemotherapy for older patients, age-related 
changes in the hypothalamic–adrenal–pituitary axis, or even 
a “response shift” in the perception of symptoms in older 
patients. Another multicenter observational study with a 
large comprehensive spectrum of active anticancer treatments 
evaluated, using BFI scale, the incidence of CRF and pain 
in cancer patients: the largest group (42.6%) comprised LC 
patients with ongoing anticancer treatment (or within a month), 
and approximately 60% demonstrated worse than moderate 
fatigue.48 In the last 10 years, some targeted therapies (TT) 
entered the therapeutic armamentarium for advanced NSCLC, 
and these new drugs are also not devoid of side effects, such 
as fatigue.49 An Italian multicenter survey evaluated the toler-
ance to TT in daily clinical practice, and about 65% of patients 
reported any grade of fatigue during treatment.50
Therapeutic approaches for fatigue in LC
Specific treatments for CFR have been investigated in a 
variety of solid tumors, and few data are currently available 
in LC. In this section, evidences with a greater impact on LC 
patients have been collected.
Pharmacological treatments
Medications with different mechanisms of action are used 
to treat CRF, including psychostimulants, phytotherapeutic 
agents, growth factors, corticosteroids, and antidepressants. 
However, for the majority of these approaches, there are no 
strong literature data supporting them as standard treatments. 
Studies with antidepressants, in particular with paroxetina, did 
not show a significant improvement of fatigue, unless in case 
of depressive disorder.51 Research has shown that 4 mg dex-
amethasone is effective for CRF.52 Nevertheless, when dexam-
ethasone is administered in patients undergoing  chemotherapy 
to prevent nausea and/or allergy, at a dosage higher than 
4 mg, fatigue is still reported. In a palliative context and for 
a short period of time, corticosteroids can improve CRF and 
increase patients’ physical activity, but prolonged use should 
be avoided in view of the risk of steroid-induced myopathy.13 
In the past, progestational steroids were often used for the 
treatment of fatigue. However, the results of a recent meta-
analysis including four trials did not show differences between 
progestational steroids versus placebo.51 Different publica-
tions describe the effectiveness of psychostimulant agents, 
such as psychostimulants methylphenidate and modafinil,53,54 
in the treatment of severe CRF, although frequent and con-
tinuous use of these drugs is not recommended because of 
the related side effects. Methylphenidate is contraindicated 
in patients with poorly controlled arterial hypertension, 
symptomatic coronary heart disease, arrhythmia, or epilepsy, 
while modafinil must be avoided in patients with psychosis 
and severe affective disorders. Furthermore, more recent 
reports do not confirm the activity of modafinil. Results of 
a randomized trial comparing modafinil versus placebo in 
208 patients with NSCLC did not show any effect on CRF 
compared to placebo.55 A meta-analysis of 1,582  participants 
treated for CRF indicated that methylphenidate was superior 
to placebo for the treatment of CRF, while no efficacy was 
shown for modafinil.56 Preliminary data highlight the role 
Lung Cancer: Targets and Therapy 2016:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
76
Carnio et al
of thyrotropin-releasing hormone in CRF  treatment and 
improvement in QoL with patients’  manifestations of exhaus-
tion, with exhaustion improving within few hours of treat-
ment.57 However, further studies are needed to confirm these 
results. There is much evidence on erythropoiesis-stimulating 
agents (ESA) in ameliorating CRF in anemic patients (also 
with LC) during chemotherapy.58 However, anemia is not 
the only cause of CRF, and these drugs are characterized by 
a toxicity profile that must be taken into account. Sleeping 
agents are frequently used to cope with CRF and insomnia 
in patients with several types of cancer, although there are 
no results clearly supporting this approach. Interesting data 
were derived from the use of melatonin agonists in patients 
with LC receiving chemotherapy.59,60 However, further studies 
need to be performed to establish this effect.
Natural remedies
Ginseng is one of the most valuable herbs and has been 
used for more than 5,000 years in oriental medicine. In the 
United States, it is currently one of the most widely used 
food supplements. Two types of ginseng are commercially 
available: American ginseng (Panax quinquefolius) and Asian 
ginseng (Panax ginseng), and several studies have shown that 
both help cope with fatigue.61–63 A recent trial investigated the 
therapeutic effects of fermented red ginseng (FRG) extract 
in 60 patients with NSCLC treated with chemotherapy. FRG 
was administered for 60 days and signifi cantly improved 
the Fatigue Symptom Inventory score, psychological status, 
physical conditions, and QoL; it was also shown to have a 
positive impact on treatment  toxicity profile.64 Preliminary 
data show the ability of purified dry extract of Paullinia 
cupana (guaraná, PC-18) to help with CRF in patients with 
solid tumors, including LC.65,66  Guaraná is an Amazonian 
plant; its main active ingredient is caffeine, but with slower 
release compared to that of pure coffee. Yiqi Jianpi Huaji 
Decoction is a traditional Chinese medicinal formula consist-
ing of 12 natural ingredients and has recently been associ-
ated with efficacy in treating CRF in LC patients receiving 
chemotherapy. Among 124 patients, 63 were assigned to 
“the treatment group” and 61 cases to the control group; 
all received chemotherapy regimens according to their 
 conditions. Patients in the treatment group took Yiqi Jianpi 
Recipe (YJR)  decoction from the first day of chemotherapy, 
one dose per day, for two consecutive weeks, while those in 
the control group took no Chinese medical decoction. The 
trial suggests that YJD decoction could significantly relieve 
CRF in LC patients, with a significant impact on QoL.67
Nonpharmacological treatments and 
complementary therapies
Several tools have been proven to be useful in alleviating 
CRF without medications. Two recent meta-analyses recom-
mend certain specific psychosocial interventions and physical 
exercise in several cancers, including LC. Physical exercise, 
negatively perceived in the past, is currently considered the 
key element in the nonpharmacological management for 
CRF.68,69 Data are more robust in preoperative regimen and 
in survivors.70,71 Physical activity has been associated with 
improvements of QoL, fatigue, and functional capacity in 
various groups of cancer survivors.72 After surgery, a signi-
ficantly reduced peak oxygen consumption per unit time 
(Vo
2
) with a decrease of patient’s ability to tolerate exercise 
has been reported.73,74 Therefore, pulmonary rehabilitation 
programs for postoperative patients with LC have shown an 
improvement in functional ability and a greater adherence 
to exercise capacity. In early-stage LC, emerging evidences 
suggest that routine exercise is associated with improvements 
in QoL and fatigue.74,75 However, a validated exercise regimen 
has not been clearly defined for perioperative or advanced-
stage LC. Several studies confirmed that increased physical 
activity may improve cluster symptoms and fatigue in patients 
with LC in the perioperative setting, although the location, 
duration, and intensity of exercise are not yet defined.76–78 Cur-
rently, the official guidelines of the American Cancer Society, 
the National Comprehensive Cancer Network, and American 
College of Sports Medicine recommend routine physical 
activity in NSCLC patients, when feasible.79–81 In addition, 
in a translational context, physical exercise could be studied in 
relation to the histological subtype and the genetic/molecular 
profile to identify patient groups more responsive to treat-
ment.82 The main recommended psychosocial interventions 
for CFR include cognitive behavioral therapeutic approaches, 
psychoeducation, topical counseling, energy conservation 
and activity management, and methods for the promotion and 
reinforcement of regeneration.83,84 However, these data were 
derived from studies of mixed tumors (mainly women with 
breast cancer). Mindfulness-based stress reduction (MBSR) 
is an interesting psychosocial intervention, and this technique 
was applied in a small group of patients with advanced-stage 
LC. The qualitative analysis showed that the training could 
instigate a process of change in participants. Significant 
differences were not found in pulmonary symptoms, fatigue, 
and pain. Although mean scores of anxiety and depressive 
symptoms in both patients and partners decreased after 
MBSR, these changes were not statistically significant.85 Data 
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from a randomized controlled trial are expected (MILON 
study):86 this trial compares MBRS with a standard approach 
in reducing psychological distress and improving QoL in 
patients with LC and their partners. The assessment of QoL 
will provide us clear details on the effect of MBRS on CRF 
in LC patients. Some studies showed that acupuncture could 
relieve pain, fatigue, and dyspnea in LC patients during all 
phases of the disease.87–89 Acupressure has been evaluated in 
two studies for its effect on CRF reaching interesting results. 
A pilot trial evaluated the effects of acupressure on fatigue 
in 57 LC patients receiving six cycles of chemotherapy: they 
were randomized into three groups, one with acupressure 
with essential oils, a second with only acupressure, and a 
third group with sham acupressure. All subjects received 
acupressure once every morning for 5 months. Subjects who 
received acupressure with essential oils and acupressure had 
significantly less fatigue in daily living activities and a bet-
ter quality of sleep at day 1, cycle three, than subjects who 
received sham acupressure.90  Several other complementary 
therapy modalities can be helpful in improving fatigue and 
QoL of patients with LC, such as hypnosis, yoga, massage 
therapy, and Tai Chi.91–93
Early palliative care in LC
The goal of palliative care is to relieve suffering and promote 
QoL for patients and families. In the past, palliative care 
 usually began at the end of active treatment. Practice guide-
lines from the World Health Organization and leadership 
from the oncology and palliative care communities advocate 
a different model of palliative care, that could be introduced 
from the point of diagnosis of life-threatening illness.94 Some 
authors evaluated early palliative care (EPC) in LC as having 
a positive benefit in QoL and physical symptoms such as pain 
and depression, already defined as symptoms associated with 
CRF.95–97 In addition, EPC may promote QoL by improving 
management of symptoms due to medical comorbidities such 
as congestive heart failure and COPD, which are often present 
in these patients. More data are clearly needed to identify the 
valid integration methods of EPC and active care.
Summary and conclusion
CRF is the most common and debilitating symptom in 
patients with cancers, including LC.5,6 In the entire  history 
of LC, from diagnosis until the end of life, fatigue is present 
in 57%–100% of patients, which has a huge influence on 
QoL.9,12,26,39,40 The incidence of fatigue can change depending 
on the time of the disease in which it is evaluated and on 
coexistence of comorbidity, cluster symptoms, and treat-
ments, which can improve or worsen the situation. Fatigue 
can be primary, when related to the tumor, while it is defined 
as secondary if it is due to treatment, nutritional status, 
laboratory abnormalities, use/abuse of substance, and/or 
comorbidities.13–17 A careful screening by using validated 
scales (quantitative and semiquantitative) is recommended 
from the time of diagnosis.18 No dedicated scale is standard-
ized for LC, and the BFI is the most widely used scale. There 
are interesting data on predictive biomarkers of primary 
CRF in NSCLC: plasma levels of TNF-α and IL-1 seem to 
be correlated with CRF.19 Several studies have identified the 
concomitance of some symptoms in patients with LC, such 
as anxiety, depression, fatigue, and sleep disturbances, that 
are commonly treated as separate entities, even though there 
are evidences suggesting their close connection, also through 
the same biological pathways.20,22,23,52 A close link exists 
between pain and fatigue and among breathing symptoms 
and fatigue.6 The vast majority of patients with LC present 
with comorbidities, such as COPD and heart diseases, that 
can worsen the CRF. Fatigue is not exclusively reported 
during the treatment of LC and at the end of life, and also 
for this reason, practice guidelines from the World Health 
Organization and leadership from the oncology and palliative 
care communities proposed the introduction of EPC in all 
cancer patients, including those with LC.94 Several studies 
have evaluated fatigue in LC survivors after radical resec-
tion.12,26–35,37 The prevalence of fatigue ranges from 60% to 
70% at 4 months after thoracotomy.30 Fatigue, small impact 
in lung function, anxiety, depression, and decreased physi-
cal activity have been observed after surgical and adjuvant 
treatments.36–38 Some authors have reported a resolution of 
symptoms at 3–6 months after surgery, while other papers 
observed persistence of these symptoms for years.33–35 The 
management of fatigue and its cluster symptoms becomes 
essential for the QoL care of patients with LC at any stage of 
the disease. Up to now, no standard treatment is recommended 
to cope with fatigue, and 4 mg of dexamethasone is the only 
drug approved for CRF.7 The use of psychostimulant agents is 
burdened by significant side effects, and modafinil use in LC 
patients has not achieved the expected results for the treat-
ment of CRF.53–56 Sleeping and antidepressant agents are often 
prescribed without any evidence supporting their use in this 
context.59,60 The administration of ESA can relieve CRF, but 
only in anemic patients undergoing chemotherapy.58 Natural 
remedies such as ginseng,61–64 cognitive behavioral therapeutic 
approaches, psychoeducation, topical  counseling,83,84 energy 
conservation as MBSR,85,86 acupuncture,87–89 acupressure,90 
hypnosis, yoga, massage therapy, and Tai Chi exercise,91–93 
have been described as valuable aids in the treatment of CRF 
in LC patients. Physical exercise is a nonpharmacological 
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treatment for fatigue, with more evidence in LC at any stage. 
Several studies have confirmed that increased physical activ-
ity may improve cluster symptoms and fatigue in patients 
with early- and advanced-stage LC, even without a precise 
schema for the application of this technique.68–82 A proposal 
for CRF management in patients with LC is described in 
Table 2. Data present in literature are often reported in a 
mixed group of tumors, not taking into account the pecu-
Table 2 Management of CRF in patients with lung cancer
Screening Revaluations
when From the diagnosis Lung cancer treated with surgery and/
or neoadjuvant/adjuvant therapya or with 
chemoradiotherapy alone
Metastatic LC
How Use of validated scales for fatigue:18 
BFI (widely used in trials in LC), FACT-F, 
CFS, MFI 
Performance status evaluation: KPS 
Use of validated scales for QoL:5 EORTC 
SF-36 QLQ-C30, SF-36 questionnaire, 
ESAS, others 
Use of validated scales for pain:20,21,23 vAS 
pain, NRS pain 
Sleep quality:23 sleep duration, trouble 
falling asleep, wake up feeling exhausted, 
sleepy during the day 
Assessment of comorbidities:22,28,29,31 
COPD, CvD, endocrine disorders 
(thyroid disease), anxiety-depressive 
syndrome, others 
Daily use of drugs:13–17 Opioids, 
benzodiazepines, neuroleptic, others 
Abuse of substances:13–17 Drugs, alcohol 
Laboratory tests:13–17 Blood count; thyroid, 
liver, and kidney function 
Presence of cluster symptoms:20,21,23,52 
Anxiety, depression (use HADS), insomnia, 
somnolence 
Presence of respiratory cluster symptoms:6 
Cough, breathlessness 
Measuring lung function with PFTs:27 
Spirometry to evaluate FEv1/FvC 
Assessment of physical activity:68–73,74–82 
Type of activity before and after the 
diagnosis. Current limitations 
Other factors:45,46 ethnicity, socioeconomic 
and social situation, family relationships
Assessment for fatigue, pain, anxiety, 
depression, insomnia, somnolence and 
respiratory cluster symptoms at regular 
intervals in time (for each symptom it is 
recommended to always use the same scale) 
Performance Status (KPS) at regular 
intervals in time 
Measuring lung function with PFTs at regular 
intervals in time 
Assessment of physical activity 
Evaluation of symptoms related to adjuvant 
chemotherapy (sensory neuropathy to the 
legs)
Assessment for fatigue, pain, anxiety, 
depression, insomnia, somnolence, and 
respiratory cluster symptoms at regular 
intervals in time during treatment (for each 
symptom, it is recommended to always use 
the same scale) 
Performance status (KPS) at each clinic visit 
Measuring lung function with PFTs at regular 
intervals in time if stable disease and no 
obvious clinic progression 
Assessment of physical activity 
Evaluation of symptoms related to 
chemotherapy, target therapy and/or 
radiotherapy (if in use active therapies)
Proposed treatment Proposed treatment
Promote pulmonary rehabilitation programs if there is a presence of deficits 
Promote physical activity based on the KPS and comorbidity 
Pain control (if present) 
Psychotherapy (if present distress)b 
Multidisciplinary approachc 
Natural remedies, complementary therapiesd 
EPC
Promote pulmonary rehabilitation programs 
if there is a presence of deficits (patients with 
COPD) 
Promote physical activity based on the KPS 
and comorbidity 
Pain control (if present) 
Psychotherapy (if present distress)b 
Multidisciplinary approachc 
Natural remedies, complementary therapiesd 
Palliative care
Notes: aChemotherapy and/or radiotherapy; bcognitive behavioral therapeutic approaches, psychoeducation, topical counseling, energy conservation and activity management, 
and methods for the promotion and reinforcement of regeneration; cif fatigue associated and/or worsened by other comorbidities (such as heart failure, thyroid disease); 
dhypnosis, yoga, and massage therapy.
Abbreviations: LC, lung cancer; BFI, Brief Fatigue Inventory; FACT-F, Functional Assessment of Cancer Therapy-Fatigue; CFS, Cancer Fatigue Scale; MFI, Multidimensional 
Fatigue Inventory; KPS, Karnofsky Performance Status; QoL, quality of life; EORTC SF-36 QLQ-C30, European Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire-Core 30; ESAS, Edmonton Symptom Assessment System; vAS, visual Analog Scale; NRS, Numeric Rating Scale; HADS, Hospital Anxiety and Depression Scale; 
COPD, chronic obstructive pulmonary disease; CvD, cardiovascular diseases; PFTs, pulmonary function tests; FEv1/FvC, forced vital capacity ratio; EPC, early palliative care.
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liarity of LC, which is frequently diagnosed in patients with 
several comorbidities; this can have a significant impact on 
fatigue. These data, together with the unpredictability of 
this tumor, should stimulate clinicians and researchers to 
develop a customized screening and treatment for CRF in 
patients with LC.
Disclosure
The authors report no conflicts of interest in this work.
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